An Observational Study on Patients With Non-Squamous NSCLC Who Reached A Long PFS After Avastin (Bevacizumab)-Based First-Line Therapy

Hoffmann-La Roche118 enrolled

Overview

This retrospective observational study will analyse demographic, clinical and treatment-related data of patients with non-squamous non-small cell lung cancer (NSCLC) who had reached \>/= 9 months of progression-free survival after Avastin (bevacizumab)-based first-line therapy. Data will be collected for approximately 9 months.

Study Type

OBSERVATIONAL

Enrollment

118

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Non-squamous non-small cell lung cancer (NSCLC) treated with first-line Avastin-based therapy * Progression-free survival of \>/= 9 months reached Exclusion Criteria: * N/A

Locations (33)

Unnamed facility

Alcoy, Alicante, Spain

Outcomes

Primary Outcomes

Progression-free survival (>9 months) according to clinical phenotype

Time frame: approximately 9 months

Secondary Outcomes

Overall survival

Time frame: approximately 9 months

Safety: Incidence of adverse events

Time frame: approximately 9 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.